The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Cost-effectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making

Author： Palmer Andrew J.   Roze Stéphane   Valentine William J.   Minshall Michael E.   Foos Volker   Lurati Francesco M.   Lammert Morten   Spinas Giatgen A.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.20, Iss.1, 2004-08, pp. : 5-26

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes

By Ray Joshua A.   Boye Kristina S.   Yurgin Nicole   Valentine William J.   Roze Stéphane   McKendrick Jan   Tucker Daniel M. D.   Foos Volker   Palmer Andrew J.  

Current Medical Research and Opinion, Vol. 23, Iss. 3, 2007-03 ,pp. : 609-622

Informa Healthcare

Access to resources Recommend Favorite

Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting

By Valentine William J.   Palmer Andrew J.   Lammert Morten   Nicklasson Lars   Foos Volker   Roze Stéphane  

Current Medical Research and Opinion, Vol. 21, Iss. 12, 2005-12 ,pp. : 2063-2071

Informa Healthcare

Access to resources Recommend Favorite

Comparing the Long-term Cost-effectiveness of Repaglinide Plus Metformin Versus Nateglinide Plus Metformin in Type 2 Diabetes Patients with Inadequate Glycaemic Control: An Application of the CORE Diabetes Model in Type 2 Diabetes

By Palmer Andrew J.   Roze Stéphane   Lammert Morten   Valentine William J.   Minshall Michael E.   Nicklasson Lars   Gall Mari-Anne   Spinas Giatgen A.  

Current Medical Research and Opinion, Vol. 20, Iss. 1, 2004-08 ,pp. : 41-51

Informa Healthcare

Access to resources Recommend Favorite

Comments and reply on: Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting

By Currie Craig J.   McEwan Phil   Poole Chris   Valentine William J.   Palmer Andrew J.   Lammert Morten   Nicklasson Lars   Foos Volker   Roze Stéphane  

Current Medical Research and Opinion, Vol. 22, Iss. 5, 2006-05 ,pp. : 967-969

Informa Healthcare

Access to resources Recommend Favorite

Clinical relevance and cost‐effectiveness of HLA genotyping in children with Type 1 diabetes mellitus in screening for coeliac disease in the Netherlands

By  

DIABETIC MEDICINE, Vol. 32, Iss. 6, 2015-06 ,pp. : 834-838

John Wiley & Sons Inc

Access to resources Recommend Favorite